- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
CURE Pharmaceutical Announces Closing of $1 Million Bridge Financing and Prepares to Uplist to NASDAQ
CURE Pharmaceutical (OTC:CURR), an innovative drug delivery and development company, today announced that it secured a $1 million bridge financing from accredited investors for working capital and the potential uplisting to NASDAQ. Alexander Capital, LP acted as the sole placement agent for the transaction. As quoted in the press release: “This capital raise takes us to …
CURE Pharmaceutical (OTC:CURR), an innovative drug delivery and development company, today announced that it secured a $1 million bridge financing from accredited investors for working capital and the potential uplisting to NASDAQ. Alexander Capital, LP acted as the sole placement agent for the transaction.
As quoted in the press release:
“This capital raise takes us to the next milestone for our company and demonstrates our maturing operations,” said Robert Davidson, CEO and Chairman of the Board of CURE Pharmaceutical. “With this investment, we will continue to develop our product pipeline and customer base always with the focus improving the patient experience through our non-invasive drug delivery products.”
Through its solutions, CURE Pharmaceutical works to better the safety and efficacy of new and existing medications. The company’s unique CUREfilm™ technology enables high loads of medicine as well as multiple actives on a single film, while maintaining fast absorption and a pleasant taste.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.